e-learning
resources
2021
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Early risk prediction in idiopathic
versus
connective tissue disease-associated pulmonary arterial hypertension: call for a refined assessment
Clara Hjalmarsson, Barbro Kjellström, Kjell Jansson, Magnus Nisell, David Kylhammar, Mohammad Kavianipour, Göran Rådegran, Stefan Söderberg, Gerhard Wikström, Dirk M. Wuttge, Roger Hesselstrand
Source:
ERJ Open Res, 7 (3) 00854-2020; 10.1183/23120541.00854-2020
Journal Issue:
July
Disease area:
Interstitial lung diseases, Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Clara Hjalmarsson, Barbro Kjellström, Kjell Jansson, Magnus Nisell, David Kylhammar, Mohammad Kavianipour, Göran Rådegran, Stefan Söderberg, Gerhard Wikström, Dirk M. Wuttge, Roger Hesselstrand. Early risk prediction in idiopathic
versus
connective tissue disease-associated pulmonary arterial hypertension: call for a refined assessment. ERJ Open Res, 7 (3) 00854-2020; 10.1183/23120541.00854-2020
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Emerging classes of drugs for the treatment of obstructive lung disease
Eosinophils and airway nerves in asthma
Related content which might interest you:
Refining definitions of time to clinical worsening in connective tissue disease-associated pulmonary arterial hypertension
Source: Annual Congress 2010 - Pulmonary hypertension
Year: 2010
Pulmonary arterial hypertension associated with connective tissue disease: an integrated approach
Source: Annual Congress 2008 - Mastering pulmonary arterial hypertension: defined by evidence - enhanced by experience
Year: 2008
Distance assessment of the risk of pulmonary hypertension associated with connective tissue diseases: do biomarkers help?
Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond
Year: 2021
Risk assessment in scleroderma patients with newly diagnosed pulmonary arterial hypertension: application of the ESC/ERS risk prediction model
Source: Eur Respir J, 52 (4) 1800497; 10.1183/13993003.00497-2018
Year: 2018
Oxygen pulse slope analysis during exercise testing identifies patients with systemic sclerosis at a possible risk for developing pulmonary vasculopathy
Source: Annual Congress 2013 –Clinical exercise physiology
Year: 2013
Tadalafil in idiopathic or heritable pulmonary arterial hypertension compared to pulmonary arterial hypertension associated with connective tissue disease
Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Year: 2011
Double combination therapy in patients with pulmonary arterial hypertension associated with connective tissue disease
Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Year: 2011
Connective tissue disease associated with pulmonary arterial hypertension: management of a patient with severe haemodynamic impairment
Source: Eur Respir Rev 2014; 23: 505-509
Year: 2014
Risk assessment in severe pulmonary hypertension due to interstitial lung disease
Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases
Year: 2020
Characteristics of idiopathic pulmonary arterial hypertension (IPAH) and PAH associated with connective tissue disease (APAH-CTD) patients in PROSPECT
Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment
Year: 2013
Non-invasive evaluation in prediction of pulmonary hypertension in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2011 - Pulmonary hypertension in hypoxic lung disease
Year: 2011
The Role of Inflammation in promoting pulmonary hypertension in idiopatchi and connective tissue disease-associated PAH
Source: Research Seminar 2008 - The Pulmonary Circulation: Scleroderma-Related Pulmonary Arterial Hypertension
Year: 2008
Severe pulmonary hypertension after the discovery of the familial primary pulmonary hypertension gene
Source: Eur Respir J 2001; 17: 1065-1069
Year: 2001
Novel biomarkers in idiopathic pulmonary arterial hypertension
Source: Annual Congress 2010 - Pulmonary hypertension
Year: 2010
Application of a formula to predict mean pulmonary artery pressures in patients with connective tissue disease
Source: Annual Congress 2010 - Pulmonary hypertension
Year: 2010
Age, risk and outcomes in idiopathic pulmonary arterial hypertension
Source: Eur Respir J, 51 (5) 1800629; 10.1183/13993003.00629-2018
Year: 2018
Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension
Source: Eur Respir J, 50 (2) 1602493; 10.1183/13993003.02493-2016
Year: 2017
Different definitions of pulmonary hypertension in interstitial lung disease: a prognostic evaluation.
Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases
Year: 2020
Lower DHEA-S levels predict disease and worse outcomes in post-menopausal women with idiopathic, connective tissue disease- and congenital heart disease-associated pulmonary arterial hypertension
Source: Eur Respir J, 51 (6) 1800467; 10.1183/13993003.00467-2018
Year: 2018
Risk assessment in patients with systemic sclerosis and pulmonary arterial hypertension
Source: Eur Respir J, 52 (4) 1801745; 10.1183/13993003.01745-2018
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept